A prospective, randomized, open-label, pilot study to compare the effect on carotid atherosclerosis of a tacrolimus-based regimen with conversion from a tacrolimus- to a sirolimus-based regimen at 3-4 months post-transplant in de novo renal transplant recipients.

Trial Profile

A prospective, randomized, open-label, pilot study to compare the effect on carotid atherosclerosis of a tacrolimus-based regimen with conversion from a tacrolimus- to a sirolimus-based regimen at 3-4 months post-transplant in de novo renal transplant recipients.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 19 Jul 2013

At a glance

  • Drugs Sirolimus (Primary) ; Mycophenolate mofetil; Mycophenolate sodium; Prednisone; Tacrolimus
  • Indications Renal transplant rejection
  • Focus Biomarker; Pharmacodynamics
  • Sponsors Pfizer
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 23 May 2012 Actual initiation date changed from Mar 2006 to Apr 2006 as reported by ClinicalTrials.gov.
    • 23 May 2012 Planned end date changed from 1 Mar 2013 to 1 Jan 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top